Celldex Therapeutics, Inc. (NASDAQ:CLDX) was the target of a significant drop in short interest in the month of May. As of May 31st, there was short interest totalling 19,015,719 shares, a drop of 4.4% from the May 15th total of 19,894,282 shares. Based on an average daily volume of 1,771,296 shares, the days-to-cover ratio is presently 10.7 days.

Large investors have recently added to or reduced their stakes in the stock. FMR LLC increased its stake in Celldex Therapeutics by 40.3% in the fourth quarter. FMR LLC now owns 19,327,111 shares of the biopharmaceutical company’s stock valued at $68,418,000 after buying an additional 5,555,595 shares during the last quarter. Vanguard Group Inc. increased its stake in Celldex Therapeutics by 16.4% in the first quarter. Vanguard Group Inc. now owns 9,066,763 shares of the biopharmaceutical company’s stock valued at $32,731,000 after buying an additional 1,278,206 shares during the last quarter. KLP Enterprises LLC bought a new stake in Celldex Therapeutics during the fourth quarter valued at approximately $24,302,000. Columbia Wanger Asset Management LLC increased its stake in Celldex Therapeutics by 113.1% in the fourth quarter. Columbia Wanger Asset Management LLC now owns 6,195,855 shares of the biopharmaceutical company’s stock valued at $21,933,000 after buying an additional 3,288,332 shares during the last quarter. Finally, State Street Corp increased its stake in Celldex Therapeutics by 4.7% in the first quarter. State Street Corp now owns 4,525,051 shares of the biopharmaceutical company’s stock valued at $16,341,000 after buying an additional 202,375 shares during the last quarter. 64.66% of the stock is owned by institutional investors.

Celldex Therapeutics (NASDAQ:CLDX) opened at 2.24 on Monday. Celldex Therapeutics has a 52-week low of $2.20 and a 52-week high of $5.02. The stock has a 50 day moving average of $3.03 and a 200-day moving average of $3.41. The company’s market cap is $280.23 million.

Celldex Therapeutics (NASDAQ:CLDX) last released its quarterly earnings data on Tuesday, May 9th. The biopharmaceutical company reported ($0.28) EPS for the quarter, meeting the consensus estimate of ($0.28). The company had revenue of $1.53 million during the quarter, compared to the consensus estimate of $0.57 million. Celldex Therapeutics had a negative return on equity of 53.10% and a negative net margin of 1,825.82%. On average, analysts forecast that Celldex Therapeutics will post ($1.11) EPS for the current year.

Several analysts recently commented on the stock. Cowen and Company restated a “buy” rating on shares of Celldex Therapeutics in a report on Tuesday, June 6th. Zacks Investment Research upgraded shares of Celldex Therapeutics from a “hold” rating to a “buy” rating and set a $3.50 price target for the company in a report on Wednesday, May 31st. HC Wainwright restated a “buy” rating and set a $6.00 price target on shares of Celldex Therapeutics in a report on Wednesday, March 15th. ValuEngine cut shares of Celldex Therapeutics from a “sell” rating to a “strong sell” rating in a report on Saturday, June 3rd. Finally, Jefferies Group LLC decreased their price target on shares of Celldex Therapeutics from $5.00 to $4.00 and set a “hold” rating for the company in a report on Wednesday, March 15th. One research analyst has rated the stock with a sell rating, two have issued a hold rating and seven have assigned a buy rating to the company’s stock. Celldex Therapeutics currently has an average rating of “Buy” and an average target price of $6.86.

TRADEMARK VIOLATION NOTICE: “Celldex Therapeutics, Inc. (CLDX) Short Interest Update” was originally published by American Banking News and is the sole property of of American Banking News. If you are accessing this article on another publication, it was stolen and reposted in violation of US and international trademark & copyright laws. The correct version of this article can be viewed at https://www.americanbankingnews.com/2017/06/12/celldex-therapeutics-inc-cldx-short-interest-update.html.

About Celldex Therapeutics

Celldex Therapeutics, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of several immunotherapy technologies for the treatment of cancer and other diseases. Its lead drug Rintega (also referred to as rindopepimut and CDX-110) is a therapeutic vaccine, which is meant for the treatment of glioblastoma patients.

Receive News & Ratings for Celldex Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.